Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 57 | 2024 | 2325 | 5.710 |
Why?
|
Hepatitis, Autoimmune | 17 | 2023 | 172 | 4.600 |
Why?
|
Cholangitis, Sclerosing | 14 | 2024 | 177 | 2.870 |
Why?
|
Alagille Syndrome | 6 | 2023 | 45 | 1.880 |
Why?
|
Biliary Atresia | 14 | 2018 | 88 | 1.480 |
Why?
|
Liver Failure | 8 | 2013 | 249 | 1.390 |
Why?
|
Liver Diseases | 9 | 2023 | 1302 | 1.350 |
Why?
|
Hepatolenticular Degeneration | 3 | 2022 | 72 | 1.240 |
Why?
|
Immunosuppressive Agents | 21 | 2020 | 4166 | 1.150 |
Why?
|
End Stage Liver Disease | 4 | 2017 | 353 | 1.140 |
Why?
|
Cholestasis | 6 | 2022 | 377 | 0.930 |
Why?
|
Graft Survival | 17 | 2021 | 3794 | 0.910 |
Why?
|
Graft Rejection | 12 | 2021 | 4426 | 0.860 |
Why?
|
Hypertension, Portal | 7 | 2022 | 226 | 0.860 |
Why?
|
Hepatopulmonary Syndrome | 2 | 2014 | 24 | 0.830 |
Why?
|
Autoantibodies | 7 | 2018 | 2118 | 0.780 |
Why?
|
Azathioprine | 4 | 2018 | 356 | 0.750 |
Why?
|
Bile Ducts | 3 | 2012 | 282 | 0.680 |
Why?
|
Cholestasis, Intrahepatic | 4 | 2021 | 75 | 0.650 |
Why?
|
Child | 75 | 2024 | 79806 | 0.640 |
Why?
|
Liver | 15 | 2018 | 7509 | 0.620 |
Why?
|
Liver Cirrhosis, Biliary | 1 | 2018 | 105 | 0.600 |
Why?
|
Fatty Liver | 3 | 2013 | 778 | 0.570 |
Why?
|
Tacrolimus | 6 | 2013 | 733 | 0.560 |
Why?
|
Pediatrics | 6 | 2017 | 3586 | 0.550 |
Why?
|
Bilirubin | 11 | 2021 | 438 | 0.540 |
Why?
|
Pancreas Transplantation | 1 | 2017 | 196 | 0.540 |
Why?
|
Lymphangioma | 1 | 2016 | 61 | 0.520 |
Why?
|
Liver Failure, Acute | 3 | 2014 | 181 | 0.510 |
Why?
|
Medication Adherence | 4 | 2013 | 2165 | 0.510 |
Why?
|
Hepatitis | 3 | 2007 | 230 | 0.500 |
Why?
|
Child, Preschool | 43 | 2023 | 42063 | 0.480 |
Why?
|
Hepatitis C | 4 | 2020 | 1579 | 0.460 |
Why?
|
Organ Transplantation | 3 | 2015 | 1150 | 0.460 |
Why?
|
Fructose Intolerance | 1 | 2013 | 8 | 0.450 |
Why?
|
Gastroenterology | 2 | 2020 | 571 | 0.450 |
Why?
|
Hepatomegaly | 1 | 2013 | 84 | 0.440 |
Why?
|
Bile Ducts, Intrahepatic | 2 | 2021 | 296 | 0.430 |
Why?
|
Liver Neoplasms | 5 | 2017 | 4319 | 0.420 |
Why?
|
Cytochrome P-450 CYP2D6 | 3 | 2003 | 107 | 0.410 |
Why?
|
Adolescent | 58 | 2024 | 87810 | 0.410 |
Why?
|
Autoimmunity | 2 | 2023 | 1370 | 0.410 |
Why?
|
Anemia, Hemolytic, Autoimmune | 3 | 2011 | 146 | 0.400 |
Why?
|
Lymphoproliferative Disorders | 3 | 2012 | 533 | 0.400 |
Why?
|
Muromonab-CD3 | 1 | 2011 | 104 | 0.380 |
Why?
|
Tyrosinemias | 1 | 2011 | 10 | 0.380 |
Why?
|
Hyperplasia | 2 | 2014 | 1155 | 0.380 |
Why?
|
Hepatitis B, Chronic | 3 | 2010 | 403 | 0.380 |
Why?
|
Spleen | 1 | 2017 | 2298 | 0.370 |
Why?
|
Intestine, Small | 1 | 2017 | 1207 | 0.370 |
Why?
|
Infant | 35 | 2023 | 36060 | 0.370 |
Why?
|
Postoperative Complications | 14 | 2017 | 15697 | 0.370 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2250 | 0.360 |
Why?
|
Giant Cells | 3 | 2007 | 185 | 0.360 |
Why?
|
Portoenterostomy, Hepatic | 5 | 2018 | 22 | 0.350 |
Why?
|
Inflammatory Bowel Diseases | 5 | 2024 | 2421 | 0.340 |
Why?
|
Antilymphocyte Serum | 1 | 2011 | 482 | 0.340 |
Why?
|
Cefotaxime | 1 | 2009 | 35 | 0.330 |
Why?
|
Vancomycin | 2 | 2024 | 503 | 0.330 |
Why?
|
Humans | 114 | 2024 | 760621 | 0.320 |
Why?
|
Continuity of Patient Care | 3 | 2010 | 1066 | 0.320 |
Why?
|
Hepatitis C, Chronic | 5 | 2020 | 1031 | 0.320 |
Why?
|
Thrombocytopenia | 2 | 2016 | 1174 | 0.320 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2012 | 608 | 0.300 |
Why?
|
Treatment Outcome | 34 | 2024 | 65017 | 0.290 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2017 | 2299 | 0.290 |
Why?
|
Cholelithiasis | 1 | 2009 | 408 | 0.290 |
Why?
|
Hyperbilirubinemia, Neonatal | 1 | 2007 | 31 | 0.290 |
Why?
|
Cholangiocarcinoma | 1 | 2013 | 550 | 0.290 |
Why?
|
Bile Duct Neoplasms | 1 | 2013 | 602 | 0.290 |
Why?
|
Self Concept | 1 | 2013 | 1039 | 0.280 |
Why?
|
Caroli Disease | 1 | 2006 | 12 | 0.270 |
Why?
|
Bile Acids and Salts | 2 | 2021 | 382 | 0.270 |
Why?
|
Ursodeoxycholic Acid | 2 | 2021 | 79 | 0.260 |
Why?
|
Male | 68 | 2024 | 359744 | 0.250 |
Why?
|
Williams Syndrome | 1 | 2007 | 193 | 0.250 |
Why?
|
Polycystic Kidney Diseases | 1 | 2006 | 133 | 0.250 |
Why?
|
Methylprednisolone | 3 | 2016 | 384 | 0.240 |
Why?
|
Affect | 1 | 2013 | 1480 | 0.240 |
Why?
|
Pemphigoid, Bullous | 1 | 2006 | 114 | 0.240 |
Why?
|
Interferon-alpha | 2 | 2010 | 918 | 0.240 |
Why?
|
Antiviral Agents | 8 | 2020 | 3061 | 0.240 |
Why?
|
Eosinophilia | 2 | 2012 | 559 | 0.240 |
Why?
|
Female | 68 | 2024 | 391270 | 0.230 |
Why?
|
Infant, Newborn | 17 | 2021 | 26181 | 0.230 |
Why?
|
Treatment Refusal | 2 | 2006 | 430 | 0.230 |
Why?
|
Avitaminosis | 2 | 2014 | 35 | 0.230 |
Why?
|
Alanine Transaminase | 6 | 2021 | 606 | 0.220 |
Why?
|
Jaundice | 1 | 2004 | 97 | 0.220 |
Why?
|
Rubella | 1 | 2023 | 55 | 0.220 |
Why?
|
Lamivudine | 1 | 2005 | 363 | 0.220 |
Why?
|
Chickenpox | 1 | 2023 | 97 | 0.210 |
Why?
|
Mycophenolic Acid | 1 | 2005 | 343 | 0.210 |
Why?
|
Mumps | 1 | 2023 | 71 | 0.210 |
Why?
|
Trientine | 1 | 2022 | 12 | 0.210 |
Why?
|
Penicillamine | 1 | 2022 | 60 | 0.210 |
Why?
|
Hepacivirus | 3 | 2020 | 1334 | 0.210 |
Why?
|
Prednisolone | 3 | 2014 | 327 | 0.200 |
Why?
|
Immunodominant Epitopes | 1 | 2003 | 241 | 0.200 |
Why?
|
Quality of Life | 6 | 2014 | 13308 | 0.200 |
Why?
|
Hemangioendothelioma | 2 | 2013 | 111 | 0.200 |
Why?
|
Cystic Fibrosis | 1 | 2011 | 1274 | 0.190 |
Why?
|
Measles | 1 | 2023 | 185 | 0.190 |
Why?
|
Lung Transplantation | 1 | 2011 | 1305 | 0.190 |
Why?
|
Risk Factors | 18 | 2021 | 74359 | 0.190 |
Why?
|
Chelating Agents | 1 | 2022 | 384 | 0.180 |
Why?
|
Cysts | 1 | 2006 | 683 | 0.180 |
Why?
|
Copper | 1 | 2022 | 368 | 0.170 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 2020 | 113 | 0.170 |
Why?
|
Follow-Up Studies | 14 | 2021 | 39261 | 0.160 |
Why?
|
Retrospective Studies | 22 | 2024 | 80372 | 0.160 |
Why?
|
Adult | 27 | 2024 | 219994 | 0.160 |
Why?
|
Viral Vaccines | 1 | 2023 | 596 | 0.150 |
Why?
|
Sirolimus | 1 | 2005 | 1547 | 0.150 |
Why?
|
Immunologic Factors | 1 | 2007 | 1588 | 0.150 |
Why?
|
Failure to Thrive | 1 | 2018 | 140 | 0.150 |
Why?
|
Young Adult | 16 | 2024 | 58741 | 0.150 |
Why?
|
Enterohepatic Circulation | 1 | 2017 | 12 | 0.150 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1869 | 0.140 |
Why?
|
Biopsy | 7 | 2020 | 6771 | 0.140 |
Why?
|
Incidental Findings | 2 | 2013 | 698 | 0.140 |
Why?
|
Self Care | 2 | 2013 | 793 | 0.140 |
Why?
|
Gallbladder | 3 | 2017 | 305 | 0.140 |
Why?
|
Glucocorticoids | 3 | 2021 | 2145 | 0.140 |
Why?
|
Adenosine Triphosphatases | 1 | 2021 | 832 | 0.140 |
Why?
|
Ultrasonography | 2 | 2013 | 5961 | 0.140 |
Why?
|
Transplantation | 2 | 2010 | 218 | 0.140 |
Why?
|
Autoantigens | 2 | 2015 | 877 | 0.130 |
Why?
|
Age Factors | 7 | 2021 | 18416 | 0.130 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1376 | 0.120 |
Why?
|
Patient Compliance | 5 | 2013 | 2688 | 0.120 |
Why?
|
Hepatorenal Syndrome | 1 | 2016 | 76 | 0.120 |
Why?
|
Cholangiography | 2 | 2020 | 181 | 0.120 |
Why?
|
Body Weight | 4 | 2018 | 4611 | 0.120 |
Why?
|
Prognosis | 9 | 2021 | 29658 | 0.120 |
Why?
|
North America | 2 | 2016 | 1284 | 0.120 |
Why?
|
Time Factors | 9 | 2021 | 40165 | 0.120 |
Why?
|
Hepatoblastoma | 1 | 2015 | 88 | 0.120 |
Why?
|
Fatal Outcome | 2 | 2017 | 1832 | 0.120 |
Why?
|
Propranolol | 2 | 2013 | 489 | 0.120 |
Why?
|
Risk Assessment | 7 | 2021 | 24123 | 0.120 |
Why?
|
Donor Selection | 1 | 2016 | 228 | 0.120 |
Why?
|
gamma-Glutamyltransferase | 3 | 2021 | 144 | 0.110 |
Why?
|
Diagnosis, Differential | 4 | 2017 | 12965 | 0.110 |
Why?
|
Survival Rate | 4 | 2013 | 12808 | 0.110 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2016 | 418 | 0.110 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 1931 | 0.110 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5889 | 0.110 |
Why?
|
Fructose-Bisphosphate Aldolase | 1 | 2013 | 51 | 0.110 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 365 | 0.110 |
Why?
|
Vitamin K | 2 | 2014 | 321 | 0.110 |
Why?
|
Steroids | 1 | 2018 | 928 | 0.110 |
Why?
|
Vincristine | 1 | 2016 | 1039 | 0.110 |
Why?
|
Sarcopenia | 1 | 2018 | 372 | 0.110 |
Why?
|
Jejunum | 2 | 2012 | 471 | 0.110 |
Why?
|
Liver Function Tests | 2 | 2012 | 524 | 0.110 |
Why?
|
Databases, Factual | 4 | 2015 | 8035 | 0.110 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2010 | 1131 | 0.100 |
Why?
|
Reoperation | 5 | 2014 | 4291 | 0.100 |
Why?
|
Recurrence | 5 | 2021 | 8482 | 0.100 |
Why?
|
Severity of Illness Index | 5 | 2024 | 15840 | 0.100 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2015 | 282 | 0.100 |
Why?
|
Viremia | 2 | 2012 | 707 | 0.100 |
Why?
|
Hemoglobin SC Disease | 1 | 2011 | 23 | 0.100 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 575 | 0.100 |
Why?
|
Vitamin E | 2 | 2014 | 872 | 0.100 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2011 | 29 | 0.100 |
Why?
|
Acetylcysteine | 1 | 2013 | 264 | 0.100 |
Why?
|
Stomach | 1 | 2016 | 694 | 0.100 |
Why?
|
Consanguinity | 1 | 2013 | 456 | 0.090 |
Why?
|
Serum Albumin | 3 | 2021 | 674 | 0.090 |
Why?
|
Microsomes, Liver | 2 | 2003 | 173 | 0.090 |
Why?
|
Calculi | 1 | 2011 | 49 | 0.090 |
Why?
|
Mycoplasma pneumoniae | 1 | 2010 | 43 | 0.090 |
Why?
|
Peptide Fragments | 2 | 2003 | 5125 | 0.090 |
Why?
|
Endoscopy, Digestive System | 1 | 2013 | 351 | 0.090 |
Why?
|
Pneumonia, Mycoplasma | 1 | 2010 | 50 | 0.090 |
Why?
|
Graves Disease | 1 | 2012 | 239 | 0.090 |
Why?
|
Obesity | 1 | 2013 | 12922 | 0.090 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2010 | 86 | 0.090 |
Why?
|
Antimetabolites | 1 | 2010 | 128 | 0.090 |
Why?
|
Antibodies, Monoclonal | 1 | 2007 | 9185 | 0.090 |
Why?
|
HLA Antigens | 1 | 2015 | 1368 | 0.090 |
Why?
|
Blood Coagulation | 1 | 2016 | 1157 | 0.090 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 830 | 0.090 |
Why?
|
Anti-Bacterial Agents | 2 | 2024 | 7408 | 0.080 |
Why?
|
Aspartate Aminotransferases | 3 | 2021 | 416 | 0.080 |
Why?
|
Premature Birth | 1 | 2021 | 1771 | 0.080 |
Why?
|
Disease Progression | 4 | 2021 | 13502 | 0.080 |
Why?
|
Allopurinol | 1 | 2010 | 198 | 0.080 |
Why?
|
Cholagogues and Choleretics | 1 | 2008 | 37 | 0.080 |
Why?
|
Acalculous Cholecystitis | 1 | 2008 | 8 | 0.080 |
Why?
|
Transaminases | 2 | 2010 | 196 | 0.080 |
Why?
|
Cohort Studies | 8 | 2024 | 41335 | 0.080 |
Why?
|
Pilot Projects | 2 | 2013 | 8555 | 0.080 |
Why?
|
Varicose Veins | 1 | 2010 | 155 | 0.080 |
Why?
|
Ganciclovir | 1 | 2009 | 252 | 0.080 |
Why?
|
Self Efficacy | 1 | 2013 | 630 | 0.080 |
Why?
|
Biopsy, Needle | 1 | 2013 | 1630 | 0.080 |
Why?
|
Health Behavior | 2 | 2010 | 2622 | 0.080 |
Why?
|
Peer Group | 1 | 2013 | 674 | 0.080 |
Why?
|
Administration, Oral | 3 | 2024 | 4035 | 0.080 |
Why?
|
Ribavirin | 1 | 2010 | 396 | 0.080 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2010 | 244 | 0.080 |
Why?
|
Colitis, Ulcerative | 1 | 2020 | 1919 | 0.070 |
Why?
|
Mentors | 1 | 2013 | 661 | 0.070 |
Why?
|
Polyethylene Glycols | 2 | 2012 | 1189 | 0.070 |
Why?
|
Drug Monitoring | 2 | 2013 | 965 | 0.070 |
Why?
|
Esophageal and Gastric Varices | 1 | 2010 | 208 | 0.070 |
Why?
|
Body Image | 1 | 2013 | 635 | 0.070 |
Why?
|
Regression Analysis | 3 | 2013 | 6360 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7475 | 0.070 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 241 | 0.070 |
Why?
|
Patient Dropouts | 1 | 2009 | 412 | 0.070 |
Why?
|
Fibrosis | 1 | 2014 | 2042 | 0.070 |
Why?
|
Fluorescent Antibody Technique | 2 | 2002 | 2471 | 0.070 |
Why?
|
Tissue Donors | 1 | 2016 | 2313 | 0.070 |
Why?
|
Hemangioma | 1 | 2011 | 728 | 0.070 |
Why?
|
Choledochal Cyst | 1 | 2006 | 25 | 0.070 |
Why?
|
Abnormalities, Multiple | 1 | 2013 | 1415 | 0.070 |
Why?
|
Prospective Studies | 9 | 2021 | 54303 | 0.060 |
Why?
|
United States | 8 | 2020 | 72461 | 0.060 |
Why?
|
Diabetes Complications | 1 | 2012 | 1341 | 0.060 |
Why?
|
Transplants | 1 | 2007 | 206 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3465 | 0.060 |
Why?
|
Vasculitis | 1 | 2009 | 523 | 0.060 |
Why?
|
Registries | 4 | 2021 | 8469 | 0.060 |
Why?
|
Platelet Count | 2 | 2020 | 777 | 0.060 |
Why?
|
Food Hypersensitivity | 1 | 2012 | 697 | 0.060 |
Why?
|
Canada | 3 | 2015 | 2128 | 0.060 |
Why?
|
Granuloma, Plasma Cell | 1 | 2005 | 80 | 0.060 |
Why?
|
Colon | 1 | 2012 | 1788 | 0.060 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 693 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2010 | 1268 | 0.060 |
Why?
|
Chickenpox Vaccine | 1 | 2023 | 40 | 0.060 |
Why?
|
Chronic Disease | 4 | 2013 | 9287 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 3804 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2012 | 1380 | 0.060 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1190 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2018 | 12427 | 0.060 |
Why?
|
Metabolic Diseases | 1 | 2010 | 686 | 0.060 |
Why?
|
Vaccines, Combined | 1 | 2023 | 70 | 0.060 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 6068 | 0.050 |
Why?
|
Abdominal Neoplasms | 1 | 2005 | 286 | 0.050 |
Why?
|
Dietary Supplements | 2 | 2014 | 3392 | 0.050 |
Why?
|
Fibrosarcoma | 1 | 2005 | 308 | 0.050 |
Why?
|
Adolescent Behavior | 1 | 2011 | 1175 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 2009 | 831 | 0.050 |
Why?
|
Radioligand Assay | 1 | 2002 | 366 | 0.050 |
Why?
|
Remission Induction | 2 | 2024 | 2392 | 0.050 |
Why?
|
Vaccines, Attenuated | 1 | 2023 | 314 | 0.050 |
Why?
|
Epitope Mapping | 1 | 2003 | 297 | 0.050 |
Why?
|
Ischemia | 1 | 2011 | 1893 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2015 | 3075 | 0.050 |
Why?
|
Postoperative Period | 1 | 2006 | 1818 | 0.050 |
Why?
|
Echocardiography | 1 | 2014 | 4981 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2013 | 1939 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14495 | 0.050 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2002 | 238 | 0.050 |
Why?
|
Health Status | 1 | 2014 | 4081 | 0.050 |
Why?
|
Cross Reactions | 1 | 2003 | 818 | 0.050 |
Why?
|
Vitamin A | 2 | 2014 | 613 | 0.040 |
Why?
|
Models, Statistical | 2 | 2013 | 5075 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6853 | 0.040 |
Why?
|
Codon, Nonsense | 1 | 2021 | 281 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2315 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2005 | 4541 | 0.040 |
Why?
|
Caregivers | 2 | 2009 | 2224 | 0.040 |
Why?
|
Postoperative Care | 2 | 2018 | 1479 | 0.040 |
Why?
|
Viral Nonstructural Proteins | 1 | 2020 | 223 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2014 | 2234 | 0.040 |
Why?
|
Hemorrhage | 1 | 2011 | 3600 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2012 | 3959 | 0.040 |
Why?
|
Acute Kidney Injury | 1 | 2010 | 1941 | 0.040 |
Why?
|
Quality Improvement | 1 | 2013 | 3836 | 0.040 |
Why?
|
Blood Glucose | 1 | 2012 | 6381 | 0.040 |
Why?
|
Insulin | 1 | 2012 | 6597 | 0.040 |
Why?
|
Reference Values | 2 | 2018 | 4925 | 0.040 |
Why?
|
Living Donors | 2 | 2013 | 636 | 0.040 |
Why?
|
Survival Analysis | 3 | 2021 | 10182 | 0.030 |
Why?
|
Cephalometry | 1 | 2018 | 382 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20509 | 0.030 |
Why?
|
Prevalence | 2 | 2012 | 15687 | 0.030 |
Why?
|
Comorbidity | 2 | 2010 | 10551 | 0.030 |
Why?
|
Sex Factors | 1 | 2010 | 10547 | 0.030 |
Why?
|
Recovery of Function | 1 | 2006 | 2985 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1004 | 0.030 |
Why?
|
Cytosol | 1 | 1999 | 887 | 0.030 |
Why?
|
Epitopes | 1 | 2002 | 2503 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 3986 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1617 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2015 | 187 | 0.030 |
Why?
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 26 | 0.030 |
Why?
|
Hypoalbuminemia | 1 | 2015 | 87 | 0.030 |
Why?
|
Self Administration | 2 | 2008 | 390 | 0.030 |
Why?
|
Patient Selection | 1 | 2007 | 4283 | 0.030 |
Why?
|
Enterostomy | 1 | 2014 | 14 | 0.030 |
Why?
|
Body Mass Index | 1 | 2012 | 12914 | 0.030 |
Why?
|
Ascites | 1 | 2015 | 338 | 0.030 |
Why?
|
Adrenergic beta-2 Receptor Antagonists | 1 | 2013 | 12 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1928 | 0.030 |
Why?
|
Los Angeles | 1 | 2013 | 243 | 0.030 |
Why?
|
Child Development | 2 | 2018 | 2285 | 0.030 |
Why?
|
Congenital Hypothyroidism | 1 | 2013 | 40 | 0.030 |
Why?
|
Membrane Glycoproteins | 1 | 2023 | 3707 | 0.030 |
Why?
|
Retinol-Binding Proteins | 1 | 2012 | 67 | 0.030 |
Why?
|
Gestational Age | 1 | 2021 | 3565 | 0.030 |
Why?
|
Prothrombin Time | 1 | 2012 | 116 | 0.030 |
Why?
|
Hepatitis A Antibodies | 1 | 2012 | 20 | 0.030 |
Why?
|
Methimazole | 1 | 2012 | 41 | 0.030 |
Why?
|
Antithyroid Agents | 1 | 2012 | 72 | 0.020 |
Why?
|
Splenomegaly | 1 | 2012 | 189 | 0.020 |
Why?
|
Free Radical Scavengers | 1 | 2013 | 211 | 0.020 |
Why?
|
alpha-Tocopherol | 1 | 2012 | 126 | 0.020 |
Why?
|
Hepatic Encephalopathy | 1 | 2013 | 144 | 0.020 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2006 | 4555 | 0.020 |
Why?
|
Hepatitis A | 1 | 2012 | 132 | 0.020 |
Why?
|
Parents | 1 | 2005 | 3549 | 0.020 |
Why?
|
Thyroid Function Tests | 1 | 2012 | 289 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2003 | 13451 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2008 | 10181 | 0.020 |
Why?
|
Growth Disorders | 1 | 2015 | 653 | 0.020 |
Why?
|
Pigmentation | 1 | 2011 | 144 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 1784 | 0.020 |
Why?
|
Hepatic Duct, Common | 1 | 2010 | 48 | 0.020 |
Why?
|
Blister | 1 | 2010 | 86 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2023 | 4938 | 0.020 |
Why?
|
Placebos | 1 | 2014 | 1668 | 0.020 |
Why?
|
Viral Load | 2 | 2010 | 3322 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2003 | 17624 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2005 | 4446 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13630 | 0.020 |
Why?
|
Postoperative Hemorrhage | 1 | 2013 | 422 | 0.020 |
Why?
|
Vitamin D | 2 | 2014 | 3291 | 0.020 |
Why?
|
Sclerosis | 1 | 2010 | 210 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2003 | 4742 | 0.020 |
Why?
|
Hypersensitivity, Immediate | 1 | 2012 | 345 | 0.020 |
Why?
|
Vasoconstrictor Agents | 1 | 2013 | 651 | 0.020 |
Why?
|
Thyroxine | 1 | 2013 | 667 | 0.020 |
Why?
|
Hepatic Artery | 1 | 2010 | 230 | 0.020 |
Why?
|
Middle Aged | 5 | 2012 | 220352 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 586 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2005 | 15289 | 0.020 |
Why?
|
Venules | 1 | 2009 | 164 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 2012 | 983 | 0.020 |
Why?
|
Mutation | 1 | 2013 | 29932 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2012 | 1600 | 0.020 |
Why?
|
Drainage | 1 | 2014 | 1161 | 0.020 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2011 | 506 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12159 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 1998 | 1796 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2010 | 6498 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 2013 | 696 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12293 | 0.020 |
Why?
|
Portal Vein | 1 | 2010 | 429 | 0.020 |
Why?
|
Adolescent Health Services | 1 | 2009 | 218 | 0.020 |
Why?
|
Physicians | 1 | 2005 | 4591 | 0.020 |
Why?
|
Kidney | 1 | 2003 | 7064 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2013 | 755 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1529 | 0.020 |
Why?
|
Aged | 4 | 2012 | 169152 | 0.020 |
Why?
|
Vitamins | 1 | 2014 | 1634 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2012 | 1259 | 0.020 |
Why?
|
Depression | 1 | 2005 | 8044 | 0.020 |
Why?
|
Dermatitis, Atopic | 1 | 2012 | 716 | 0.020 |
Why?
|
Drug Resistance, Viral | 1 | 2010 | 859 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2009 | 755 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2002 | 20080 | 0.010 |
Why?
|
Rhinitis | 1 | 2012 | 746 | 0.010 |
Why?
|
Hospitals, Pediatric | 1 | 2013 | 1854 | 0.010 |
Why?
|
Social Class | 1 | 2013 | 2005 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2375 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2145 | 0.010 |
Why?
|
Body Height | 1 | 2010 | 1570 | 0.010 |
Why?
|
HIV Infections | 1 | 2010 | 17165 | 0.010 |
Why?
|
Psychological Tests | 1 | 2005 | 639 | 0.010 |
Why?
|
Hepatocytes | 1 | 2010 | 1229 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2009 | 1109 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2013 | 5201 | 0.010 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2008 | 819 | 0.010 |
Why?
|
Antigen-Antibody Reactions | 1 | 2002 | 346 | 0.010 |
Why?
|
DNA, Viral | 1 | 2009 | 2194 | 0.010 |
Why?
|
Binding Sites, Antibody | 1 | 2002 | 337 | 0.010 |
Why?
|
Immune Sera | 1 | 2002 | 613 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2013 | 25942 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2010 | 4810 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13314 | 0.010 |
Why?
|
Binding, Competitive | 1 | 2002 | 1142 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 2010 | 1299 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2010 | 1801 | 0.010 |
Why?
|
Attitude | 1 | 2005 | 777 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2005 | 13262 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2010 | 6538 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4122 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2015 | 4215 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 29749 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6544 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3725 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 13981 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2010 | 2093 | 0.010 |
Why?
|
Surface Properties | 1 | 2002 | 1161 | 0.010 |
Why?
|
Communication | 1 | 2013 | 3849 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2002 | 1693 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12531 | 0.010 |
Why?
|
Age Distribution | 1 | 2004 | 2893 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2002 | 2753 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1997 | 374 | 0.010 |
Why?
|
Thrombosis | 1 | 2010 | 3052 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 12960 | 0.010 |
Why?
|
Incidence | 1 | 2013 | 21392 | 0.010 |
Why?
|
Heart Transplantation | 1 | 2008 | 3224 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22053 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11712 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2002 | 3735 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5799 | 0.010 |
Why?
|
Depressive Disorder | 1 | 2005 | 3726 | 0.010 |
Why?
|
Models, Molecular | 1 | 2002 | 5434 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 3726 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 1997 | 2852 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2012 | 58995 | 0.000 |
Why?
|